Literature DB >> 30948625

Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis.

Wallace J Brownlee1, Bhavana Solanky2, Ferran Prados2,3, Marios Yiannakas2, Patricia Da Mota2, Frank Riemer4, Manuel Jorge Cardoso3, Sebastian Ourselin3, Xavier Golay5, Claudia Gandini Wheeler-Kingshott2,6,7, Olga Ciccarelli2,8.   

Abstract

OBJECTIVE: Sodium (23Na)-MRI is an emerging imaging technique to investigate in vivo changes in tissue viability, reflecting neuroaxonal integrity and metabolism. Using an optimised 23Na-MRI protocol with smaller voxel sizes and improved tissue contrast, we wanted to investigate whether brain total sodium concentration (TSC) is a biomarker for long-term disease outcomes in a cohort of patients with relapse-onset multiple sclerosis (MS), followed from disease onset.
METHODS: We performed a cross-sectional study in 96 patients followed up ~ 15 years after a clinically isolated syndrome (CIS) and 34 healthy controls. Disease course was classified as CIS, relapsing-remitting MS or secondary progressive MS (SPMS). We acquired 1H-MRI and 23Na-MRI and calculated the TSC in cortical grey matter (CGM), deep grey matter, normal-appearing white matter (WM) and WM lesions. Multivariable linear regression was used to identify independent associations of tissue-specific TSC with physical disability and cognition, with adjustment for tissue volumes.
RESULTS: TSC in all tissues was higher in patients with MS compared with healthy controls and patients who remained CIS, with differences driven by patients with SPMS. Higher CGM TSC was independently associated with Expanded Disability Status Scale (R2=0.26), timed 25-foot walk test (R2=0.23), 9-hole peg test (R2=0.23), Paced Auditory Serial Addition Test (R2=0.29), Symbol Digit Modalities Test (R2=0.31) and executive function (R2=0.36) test scores, independent of grey matter atrophy.
CONCLUSIONS: Sodium accumulation in CGM reflects underlying neuroaxonal metabolic abnormalities relevant to disease course heterogeneity and disability in relapse-onset MS. TSC and should be considered as an outcome measure in future neuroprotection trials. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30948625      PMCID: PMC7611428          DOI: 10.1136/jnnp-2018-319634

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

1.  Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.

Authors:  W J Brownlee; D R Altmann; P Alves Da Mota; J K Swanton; K A Miszkiel; Cam Gandini Wheeler-Kingshott; O Ciccarelli; D H Miller
Journal:  Mult Scler       Date:  2016-08-06       Impact factor: 6.312

2.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

Authors:  L B Krupp; N G LaRocca; J Muir-Nash; A D Steinberg
Journal:  Arch Neurol       Date:  1989-10

Review 5.  Grey matter pathology in multiple sclerosis.

Authors:  Jeroen J G Geurts; Frederik Barkhof
Journal:  Lancet Neurol       Date:  2008-09       Impact factor: 44.182

6.  Gray matter atrophy is related to long-term disability in multiple sclerosis.

Authors:  Leonora K Fisniku; Declan T Chard; Jonathan S Jackson; Valerie M Anderson; Daniel R Altmann; Katherine A Miszkiel; Alan J Thompson; David H Miller
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  Brain intra- and extracellular sodium concentration in multiple sclerosis: a 7 T MRI study.

Authors:  Maria Petracca; Roxana O Vancea; Lazar Fleysher; Laura E Jonkman; Niels Oesingmann; Matilde Inglese
Journal:  Brain       Date:  2016-01-20       Impact factor: 13.501

Review 9.  Progressive multiple sclerosis: pathology and pathogenesis.

Authors:  Hans Lassmann; Jack van Horssen; Don Mahad
Journal:  Nat Rev Neurol       Date:  2012-09-25       Impact factor: 42.937

10.  A multi-time-point modality-agnostic patch-based method for lesion filling in multiple sclerosis.

Authors:  Ferran Prados; Manuel Jorge Cardoso; Baris Kanber; Olga Ciccarelli; Raju Kapoor; Claudia A M Gandini Wheeler-Kingshott; Sebastien Ourselin
Journal:  Neuroimage       Date:  2016-07-01       Impact factor: 6.556

View more
  10 in total

1.  Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event.

Authors:  Sara Collorone; Ferran Prados; Baris Kanber; Niamh M Cawley; Carmen Tur; Francesco Grussu; Bhavana S Solanky; Marios Yiannakas; Indran Davagnanam; Claudia A M Gandini Wheeler-Kingshott; Frederik Barkhof; Olga Ciccarelli; Ahmed T Toosy
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

Review 2.  Does Siponimod Exert Direct Effects in the Central Nervous System?

Authors:  Markus Kipp
Journal:  Cells       Date:  2020-07-24       Impact factor: 6.600

Review 3.  Magnetic Resonance Imaging as a Prognostic Disability Marker in Clinically Isolated Syndrome and Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Amjad I AlTokhis; Abrar AlAmrani; Abdulmajeed Alotaibi; Anna Podlasek; Cris S Constantinescu
Journal:  Diagnostics (Basel)       Date:  2022-01-21

4.  A generalized deep learning network for fractional anisotropy reconstruction: Application to epilepsy and multiple sclerosis.

Authors:  Marta Gaviraghi; Antonio Ricciardi; Fulvia Palesi; Wallace Brownlee; Paolo Vitali; Ferran Prados; Baris Kanber; Claudia A M Gandini Wheeler-Kingshott
Journal:  Front Neuroinform       Date:  2022-08-05       Impact factor: 3.739

Review 5.  The modulatory effect of high salt on immune cells and related diseases.

Authors:  Xian Li; Aqu Alu; Yuquan Wei; Xiawei Wei; Min Luo
Journal:  Cell Prolif       Date:  2022-06-23       Impact factor: 8.755

6.  Comparison of Neurite Orientation Dispersion and Density Imaging and Two-Compartment Spherical Mean Technique Parameter Maps in Multiple Sclerosis.

Authors:  Daniel Johnson; Antonio Ricciardi; Wallace Brownlee; Baris Kanber; Ferran Prados; Sara Collorone; Enrico Kaden; Ahmed Toosy; Daniel C Alexander; Claudia A M Gandini Wheeler-Kingshott; Olga Ciccarelli; Francesco Grussu
Journal:  Front Neurol       Date:  2021-06-14       Impact factor: 4.003

7.  Uncompromised MRI of knee cartilage while incorporating sensitive sodium MRI.

Authors:  S Brinkhof; A Ali Haghnejad; K Ito; K Markenroth Bloch; D W J Klomp
Journal:  NMR Biomed       Date:  2019-09-10       Impact factor: 4.044

Review 8.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

Review 9.  Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis.

Authors:  Maria Petracca; Giuseppe Pontillo; Marcello Moccia; Antonio Carotenuto; Sirio Cocozza; Roberta Lanzillo; Arturo Brunetti; Vincenzo Brescia Morra
Journal:  Brain Sci       Date:  2021-03-09

10.  Sodium Intensity Changes Differ Between Relaxation- and Density-Weighted MRI in Multiple Sclerosis.

Authors:  Robert Stobbe; Annie Boyd; Penelope Smyth; Derek Emery; Diana Valdés Cabrera; Christian Beaulieu
Journal:  Front Neurol       Date:  2021-07-14       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.